Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7457587 | 0.95 | L3MBTL1 (0.54) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL30683848 | 0.95 | L3MBTL1 (0.54) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL31382077 | 0.89 | SIGMAR1 (0.61) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL1465128 | 0.84 | SIGMAR1 (0.50) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL20790150 | 0.84 | OPRM1 (0.50) | SIGMAR1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL8747217 | 0.83 | SIGMAR1 (0.49) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL10002496 | 0.83 | LMNA (0.53) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL3141852 | 0.82 | TSHR (0.44) | L3MBTL1KMT2AHTTLPAR1CA12 | |
| SCHEMBL20790239 | 0.82 | CA12 (0.46) | L3MBTL1CTSDCA12CA1CA2 | |
| SCHEMBL21034824 | 0.81 | SIGMAR1 (0.47) | SIGMAR1L3MBTL1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3736270-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277273-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2019-03-14 | — | — | US | disclosed |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20200277273-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SIGMAR1 1253/4885L3MBTL1 3452/4885HDAC3 2236/4885 |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | SIGMAR1 1722/4885L3MBTL1 4254/4885HDAC3 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.